En Carta Diagnostics
Low-cost, high-accuracy paper-based diagnostics for detecting pandemics, epidemics, and bacterial resistance.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | €1.5m | Seed | |
| Total Funding | 000k | ||
Related Content
En Carta Diagnostics is building a pipeline of diagnostics as easy to use as a rapid test, as precise as a PCR machine ($27B market, 24% CAGR), starting with the early diagnosis of Lyme disease.
Our potential: transforming any smartphone into a PCR machine to bring better care everywhere.
We raised a 2M€ seed round in 2024 and hit all our milestones ahead of schedule.
Summary of our traction so far:
1st in-man diagnostic Aug 2025
2M€ seed round april 2024
Working portable Lyme diagnostic with clinical sensitivity and specificity
Scalable, cost-effective and fabless industrial roadmaps designed with partners.
Co-founded by two ex-Harvard Wyss, University of Toronto and Boston University Profs. - DARPA and NIH Awards winners (ex: $17M DARPA project)
Patented technology with exclusive worldwide license + portfolio of patent
5 prototypes built